Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.

CONCLUSION: The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m2, when combined with the 5-weekly SP regimen.
PMID: 31487733 [PubMed - as supplied by publisher]

Source: Oncology - September 4, 2019 Category: Cancer & Oncology Authors: Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, Kodera Y Tags: Oncology Source Type: research